Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Status unconfirmed · Phase 2

Conditions studied: Leukemia, Myelodysplastic Syndromes

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining topotecan and cytarabine given with amifostine in treating patients who have myelodysplastic syndrome.

Key facts

Study ID

NCT00003827

Run by

ALZA

People needed

25

Starts

1999-01-01

Last updated by the study team

2013-12-04

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cancer Center and Beckman Research Institute, City of Hope — Duarte, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.